Recent Updates
Recently added Catalysts

carmustine

Phase 3

Lymphoma | Small molecule | Oncology |Solid Biosciences Inc.|Last Updated: Sep 17, 2013

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment460
FDA Designations
No designations recorded
Clinical trial landscape

carmustine · 1 trial · 1 indication

Phase 3 1
NCT00005589Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaLymphoma
COMPLETED460 Analytics
PHASE3COMPLETED
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Lymphoma
NCT00005589460
Unlock trial analytics
Study Endpoints
Primary Endpoints
Time to disease progression
Secondary Endpoints
Response rate and survival
Molecular remission rates
Safety
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
filgrastimBIOLOGICAL -
rituximabBIOLOGICAL -
carmustineDRUG -
cyclophosphamideDRUG -
cytarabineDRUG -
etoposideDRUG -
melphalanDRUG -
bone marrow ablation with stem cell supportPROCEDURE -
peripheral blood stem cell transplantationPROCEDURE -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites131

DISEASE CHARACTERISTICS: * Relapsed or resistant follicular non-Hodgkin's lymphoma (NHL) * No evidence of transformation to high grade or diffuse large B-cell NHL * CD20 positive with no evidence of transformation * Achievement of complete remission (CR) or very good partial remission (VGPR) fol...

Countries:AustraliaAustriaBelgiumCanadaCzechiaDenmarkFranceGermanyIsraelNew ZealandPolandPortugalSpainSwedenSwitzerlandTurkey (Türkiye)United Kingdom
Unlock Eligibility Criteria
Competitive Landscape -Lymphoma 338 trials

Top 20 of 68 competitors

CompanyTickerTrialsLead PhaseDrugs
Regeneron Pharmaceuticals, Inc.REGN7PHASE3Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine
Eli Lilly and CompanyLLY12PHASE3Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
AstraZeneca PLCAZN14PHASE3Surovatamig, R-CHOP, R-CVP, BR
Merck & Co., Inc.MRK16PHASE3Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab
AbbVie, Inc.ABBV11PHASE3Venetoclax
Novartis AG Sponsored ADRNVS8PHASE3Tisagenlecleucel, Lenalidomide and rituximab in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone in 21-day cycles for 6 to 8 cycles, Lymphodepleting chemotherapy
Incyte CorporationINCY16PHASE3Tafasitamab, Lenalidomide
BeOne Medicines Ltd. Sponsored ADRONC20PHASE3BGB-16673, Bendamustine, Rituximab, Methylprednisolone, Chlorambucil
Gilead Sciences, Inc.GILD7PHASE3Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab
Genmab A/S Sponsored ADRGMAB18PHASE3Epcoritamab, Rituximab, Lenalidomide
Bristol-Myers Squibb CompanyBMY17PHASE3Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine
Johnson & JohnsonJNJ11PHASE3Ibrutinib
Pfizer Inc.PFE4PHASE3Brentuximab vedotin, Rituximab, Lenalidomide
Nurix Therapeutics, Inc.NRIX6PHASE3NX-5948, Pirtobrutinib
ADC Therapeutics LtdADCT4PHASE3Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin
Corvus Pharmaceuticals, Inc.CRVS2PHASE3Soquelitinib, Belinostat, Pralatrexate
Grifols, S.A. Sponsored ADR Class BGRFS1PHASE3Xembify
HUTCHMED (China) Limited Sponsored ADRHCM2PHASE3HMPL-760, R-GemOx
Nuvalent, Inc. Class ANUVL1PHASE3Neladalkib, Alectinib
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK6PHASE2Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Unlock Competitive Intelligence